Rapid Micro Biosystems (Nasdaq: RPID) said it will sponsor the PDA Pharmaceutical Microbiology Conference 2026 in Washington, D.C., October 26-28, and invites visitors to Booth 101. Its Growth Direct platform will be featured in a presentation by Sophia Pfeiffer of Boehringer Ingelheim on Monday, October 26 at 1:10 p.m. ET, covering early detection of mold contamination using computer vision and AI. The company describes Growth Direct as an industry-leading, fully automated, non-destructive, growth-based platform for microbial quality control testing.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on manilatimes.net ↗
Keywords
Rapid Micro Biosystemspharmaceuticalshealthcareartificial intelligence
Open a keyword to see other news on the same topic.
Related news
- Healthcare and Life Sciences Leaders Build on NVIDIA to Advance Drug Discovery and Expand Patient Care
NVIDIA and the UW Medicine Institute for Protein Design debuted RFD4-Proteina, an open model that combines programmable protein design with search capabilities so scientists and agents can refine designs using constraints and scoring objectives. In reported testing, it achieved higher computational design success rates and throughput than baselines across 4 benchmark suites. Siemens Healthineers is working with NVIDIA on next-generation adaptive radiotherapy using agentic co-planning, patient-specific simulation and robotic control. Automata, Benchling, Danaher and others are using the BioNeMo platform to build scientific agents that link drug design, autonomous labs and biological discovery. Projections show about 35 million people worldwide will be diagnosed with cancer each year by 2050.
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
- Changes to This $100 Billion Federal Drug Program Could Make Banks the Hidden Beneficiaries
A proposed overhaul of the $100 billion federal 340B drug-discount program would shift some discounts to rebates starting January 1, 2027, so hospitals must pay upfront and wait for reimbursement. In an illustrative example, an extra $10 million balance at 6% annual interest would cost about $50,000 per month, which could increase demand for credit lines from banks that already serve hospitals. The American Hospital Association estimates administrative costs could exceed $1 billion per year, compared with HRSA's $537 million estimate for submitting claims. The article notes the incremental lending demand is unquantified, and the program faces a lawsuit filed on October 9 after an earlier rebate pilot was blocked in December 2025. Banks would benefit only if added interest exceeds funding costs and credit losses.
- Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
Alnylam shares have fallen more than 40% year to date, even though the company is now solidly profitable, with Q2 2026 GAAP net income of $164.5 million and revenue up 67% to $1.29 billion. The author attributes much of the selloff to two concerns: Alnylam cut its 2026 revenue guidance for Amvuttra and Onpattra to $4.2–4.5 billion from $4.4–4.7 billion as demand normalized after an initial surge of patients switching to Amvuttra, and disappointing Phase 3 results for Wainua in ATTR-CM raised worries about Alnylam's nucresiran. The author argues both concerns are overstated, since the two drugs use different mechanisms and Amvuttra sales continue to grow robustly. Of the 23 analysts who rated the stock over the past three months, 19 recommended buying, and the average 12-month price target implies 54% upside.
- Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice
- Prime Minister: Overpriced medicines and medical equipment cause major losses for patients and the State
At a National Assembly group session on the morning of 21/10, discussing several health-sector draft laws, Prime Minister Lê Minh Hưng said medicines and medical equipment have been overpriced due to too many intermediary steps, causing major losses for patients, the state budget and the Health Insurance Fund. Inspections and investigations found many loopholes in laws, circulars and implementation, including a case involving Công ty cổ phần Đầu tư y tế Việt Mỹ, where multiple foreign companies traded goods among themselves, inflating prices and evading taxes. The government proposes urgent amendments to cut intermediaries, increase transparency, and set different procurement mechanisms: centralized bidding for common goods and direct negotiation for specialized items. The Prime Minister stressed that businesses may earn reasonable profits, but the State must control this sensitive sector.
Related markets
Latest news
- 3 ETFs That Can Weather Stock Market Volatility
The article argues that for many investors, the best approach to a bear market is to buy low-cost index funds tracking the total U.S. stock market and hold through short-term declines. It highlights three ETFs, each with a 0.03% expense ratio: the Vanguard S&P 500 ETF (VOO), the Vanguard Morningstar Total Stock Market ETF (VTI) and the Schwab U.S. Broad Market ETF (SCHB). Since inception, VOO has averaged about 14.9% a year over 16 years, SCHB about 14.3% over nearly 17 years, and VTI about 9.4% over 25 years, including the 2008 financial crisis. Although these funds hold major tech stocks, they are more diversified than the tech-heavy Nasdaq-100, and in the 2022 bear market they performed much better than that index.
- A New Mexico Judge Ordered Meta to Pay $25 Billion For a Case. Its Stock is Still Climbing.
A New Mexico judge ordered Meta to pay $25 billion after a jury found the company misled consumers about the privacy of their data a decade ago. Judge Francis Mathew said Facebook's wrongdoing, which lasted for years, went to the heart of its core business practices. New Mexico Attorney General Raul Torrez said the ruling could be the largest verdict by a single state against the company. Meta shares still rose 1.77% to above $706.5 in the afternoon ET, and the company is likely to appeal. The case is tied to the Cambridge Analytica scandal, in which data from close to 90 million Facebook users was harvested without consent through a third-party app.
- Judge orders Meta to pay $25 billion to New Mexico for violations of state law
A Santa Fe district judge ordered Meta Platforms to pay New Mexico $25 billion after a jury found the company made false statements in violation of the state's Unfair Practices Act. The jury found 43.9 million violations, with 26 of 29 statements deemed false or deceptive, affecting nearly 1.4 million New Mexico Facebook users. Judge Francis Mathew wrote that Meta 'willfully and intentionally' misled the public, including through statements by CEO Mark Zuckerberg and former COO Sheryl Sandberg. Attorney General Raúl Torrez called it one of the largest financial penalties against a corporation in U.S. history. The case stems from a 2021 lawsuit over the Cambridge Analytica data scandal.
- SpaceX gives the AI trade a shot in the arm. What it means for our stocks
SpaceX shares rose about 7% after the company reported strong third-quarter results and a robust outlook through year-end and into 2027. The article argues that SpaceX's rocket, AI and connectivity business touches many layers of the AI supply chain, from power and semiconductors to data center infrastructure, models and applications. Musk said the main constraint on deploying AI compute is now power, cooling and infrastructure rather than chips, and SpaceX plans to bring 2.5 to 3 gigawatts of compute online by year-end and about 10 GW in 2027. Its agentic AI product Grok Bot previously had 800,000 paid weekly users, and the article points to GE Vernova and Eaton as possible beneficiaries of this demand.
- XRP Price Prediction: What Would It Actually Take for XRP to Hit $210?
The article questions a $210 XRP price target, noting XRP traded at $1.36 on October 21, 2026, with a market value of about $85.6 billion. Reaching $210 would require a market cap of about $13.26 trillion, roughly 7.9 times Bitcoin's $1.68 trillion and far above XRP's all-time high of $3.65 set on July 17, 2025. U.S. spot XRP ETFs have drawn about $1.8 billion in total net inflows, but recorded zero net inflows on October 19 and 20, and XRP has fallen 27.3% year to date despite Ripple announcements. The article concludes that reaching $210 soon is unlikely and that a more realistic path would first see XRP recover to $1.84, then $2.42, before testing its record high.
- Are Bonds Pricing In A Fed Policy Mistake?
Ten-year US Treasury yields surged to 5.33% after the October 14 CPI report, then fell to 5.03% a few days later despite hotter-than-expected inflation data. Mohamed El-Erian cited two AI-related reasons: a flight to quality out of tech stocks under pressure (the SOX index fell almost 20%), and slower AI spending that could weaken growth and inflation. The author adds short covering, as asset managers added more than 100,000 contracts to short 10-year Treasury futures, and a strong $39 billion 10-year auction at 5.300% that drew more demand than expected. The article argues the bond market may be pricing in the risk that the Federal Reserve is being pushed into a policy mistake.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.